Comparing Invivyd (IVVD) & Its Peers

Invivyd (NASDAQ:IVVD) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Invivyd to related businesses based on the strength of its earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Valuation and Earnings

This table compares Invivyd and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Invivyd	$53.43 million	-$52.49 million	-1.74
Invivyd Competitors	$702.95 million	$10.43 million	-15.13

Invivyd’s rivals have higher revenue and earnings than Invivyd. Invivyd is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Invivyd and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Invivyd Competitors	-12,285.98%	-196.04%	-30.61%

Analyst Recommendations

This is a summary of current ratings and target prices for Invivyd and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1	2	3	0	2.33
Invivyd Competitors	9858	15137	45528	1590	2.54

Invivyd presently has a consensus price target of $10.00, suggesting a potential upside of 1,640.95%. As a group, “Biotechnology” companies have a potential upside of 99.28%. Given Invivyd’s higher probable upside, equities research analysts plainly believe Invivyd is more favorable than its rivals.

Risk & Volatility

Invivyd has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Invivyd’s rivals have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.

Institutional & Insider Ownership

70.4% of Invivyd shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 12.2% of Invivyd shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Invivyd rivals beat Invivyd on 7 of the 12 factors compared.

Invivyd Company Profile

Invivyd, Inc. is a biotechnology company focused on developing antibody-based medicines designed to prevent and treat infectious diseases. The company uses its antibody discovery and engineering technologies to create broadly neutralizing antibodies intended to remain effective as viruses evolve. Invivyd’s lead product is pemivibart, marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration granted pemivibart an Emergency Use Authorization in 2024 for pre-exposure prophylaxis against COVID-19 in certain individuals who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to vaccination.